wedbush calendar upcom event
reiter neutral rate share target compani still pre-commerci stage develop
 updat impact share quarterli print stage notabl financi report
manag continu anticip phase parkinson diseas data inhibitor
earli addit effort track advanc mp ii program toward clinic bottom line
continu hold posit bia pipelin develop effort howev current valuat continu
price much success await compel entri point get construct share chang
estim target remain
financi revenu guidanc rais pipelin progress
aquest therapeut leverag proprietari pharmfilm technolog improv deliveri establish drug activ
ingredi wholly-own partner pipelin candid novemb aquest report total
revenu beat bloomberg consensu estim manag rais guidanc total revenu
previous manufactur revenu top end previou
guidanc due slow eros brand market suboxon despit gener competit
late novemb compani anticip complet roll nda submiss liberv diazepam buccal film
treatment acut refractory/repetit seizur assum standard month review estim potenti pdufa
date late conserv project annual sale million potenti launch octob
compani expect peak net revenu exservan oral solubl film formul riluzol
al anticip potenti approv novemb pdufa date recal compani previous
report promis phase proof-of-concept data sublingu film formul epinephrin treatment
anaphylaxi sever allerg reaction pleas see septemb research note request pre-ind
meet fda discuss potenti develop pathway aquest announc poster present
embargo novemb american epilepsi societi annual meet decemb baltimor
decemb aquest plan sponsor scientif exchang meet discuss expand liberv clinic data
set well host corpor day see aqst attract invest ahead key regulatori catalyst
recommend share investor
exservan/ al novemb pdufa date continu monitor weekli sympazan sale symphoni
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
financi unev pfic close enrol top-line data mid
albireo emerg pharmaceut compani focus develop bile acid modul drug treatment
liver gastrointestin diseas novemb compani report million revenu ep loss
compar bloomberg consensu million respect albireo end quarter
million cash equival project runway manag highlight clinic trial enrol phase
trial odevixibat progress famili intrahapet cholestasi pfic patient subtyp end
octob patient trial random enough patient screen complet trial
enrol estim enrol complet odevixibat/biliari atresia discuss on-going fda
compani plan initi phase trial elobixibat/nash top-lin phase data anticip
view next key catalyst stock top-lin result phase trial odevixibat/pf
look durabl efficaci treatment clean safeti
estim odevixibat/pf phase pedfic enrol complet
financi updat tipifarnib aitl patient ahead
continu ration broaden lead asset tipifarnib clinic develop program ahead like posit
outcom registration-direct studi hras-mut head neck squamou cell carcinoma hnscc
present addit data aitl patient expect provid critic insight initi
regulatori strategi go forward indic addit data on-going studi addit hras-
driven cancer report continu view one top pick reiter outperform rate
price target
report net loss line estim compani end quarter
cash equival manag expect fund on-going oper
a-d-c updat
wedbush view advanc anti-sodium-depend phosphat transport protein antibodi
drug conjug dolalock payload intend tumor non-smal cell lung cancer
adenocarcinoma ovarian cancer compani continu enrol patient ph dose expans studi evalu
dose regimen diagnos platinum-resist ovarian cancer
therapi nsclc adenocarcinoma fail prior line platinum-bas chemotherapi therapi on-going
ph dose escal studi also evalu dose level report date well toler
among three evalu patient dose limit toxic assess safeti review committe find
earli safeti report encourag compani look forward readout dose escal
expans studi expect deeper insight toler efficaci furthermor look add anoth
program pipelin remain commit name next develop candid around year end
file ind societi immunotherapi cancer meet later week present
preclin data abstract titl tumor target sting agonist antibodi drug conjug elicit potent anti-
cell therapi program begin take shape updat await
wedbush view report quarterli financi provid insight sever data present
societi immunotherapi cancer american societi hematolog meet among clinic updat
initi enrol cell dose level immun checkpoint inhibitor ici combin
arm date treat three patient fail prior ici therapi combin arm cell dose level
patient monotherapi arm studi pt cell dose level pt cell dose level
dose limit toxic treatment-rel seriou advers event report upon establish cell
dose level safe intend initi dose expans arm amend studi allow enrich tumor
partial complet loss mhc class express add cytokin support nk-cell activ induct select cancer
amen nk-cell infiltr dr jeff miller univers minnesota schedul present pre-
clinic data sunday show anti-tumor synerg checkpoint inhibitor therapi dec
expect initi safeti toler well insight plan dose expans studi design friday
decemb host investor event dr miller two memori sloan-kett cancer center expert
dr eric smith dr michel sadelain program updat includ preclin data
updat particular interest given fda recent clear ind applic
engin off-the-shelf chimer antigen receptor nk cell cancer immunotherapi target carri
fc receptor receptor fusion alreadi open ph studi aim treat first patient
earli studi first investig safeti monotherapi cell per dose combin
rituximab advanc b-cell lymphoma cell per dose plan combin obinutuzumab
chronic lymphocyt leukemia follow tabl present titl compil figur final open
cgmp manufactur facil san diego in-hous manufactur compani off-the-shelf nk cell t-
program updat first patient treat octob off-the-shelf nk
immunotherapi engin express non-cleav fc receptor address relapsed/refractori hematolog
malign evalu across three regimen regimen aml monotherapi regimen non-hodgkin
lymphoma combin rituximab regimen multipl myeloma combin elotuzumab
pomalidomid dexamethason regimen one patient interestingli manag fulli
close door regard possibl see clinic updat though think updat unlik
also complet enrol ph protect studi protmun prevent acut graft-versus-host
diseas gvhd patient undergo hematopoiet cell transplant data updat expect
financi system mastocytosi focu day pioneer
wedbush view attend bpmc day new york center lead candid avapritinib potenti
address advanc indol form system mastocytosi system mastocytosi sm blood disord
character aberr mast cell activ prolifer result poor prognos extens organ dysfunct
failur case advanc sm debilit highli divers symptomolog skin rash hypersensit gi
effect extens psychosoci impact case indol sm believ avapritinib posit potenti
best-in-class agent address advanc indol form diseas given highli select potent activ
form sm common genet driver kit mutat ph explor data date clinic valid
scientif rational advanc sm show signific improv key biomark correl deep durabl
respons well signific improv pt total symptom score use bpmc-creat tool improv
toler rel best-avail treatment base find anticip submit nda ava
advanc sm expect approv commerci launch late current model sale
estim advanc sm see increas almost valu
indic note see room upsid estim diseas awar diagnost effici
improv given factor like contribut epidemiolog estim meaning underst
claim data show identifi sm pt us current
addit advanc sm highlight avapritinib promis indol sm offer appreci attract
opportun given larger market roughli split advanced/indol sm high unmet need
approv therapi exploratori explor analysi inappropri enrol indol pt establish clinic proof-
of-concept pt shown signific biomark improv durabl treatment durat nearli
three year lower dose level look forward initi ph pioneer data evalu avapritinib enrol
pt dose-find portion studi present poster session year american hematolog
associ meet decemb abstract discuss later investor event night begin
pm et webcast select anticip initi registration-direct random
placebo-control expans portion studi addit expand therapeut focu sm
compani introduc newly-nomin preclin candid repres next-gener select kit
inhibitor notabl without penetr abil allow improv toler broader set sm pt potenti
expans addit mast cell disord ind submiss anticip
egfrmut nsclc program focus target common acquir resist mutat standard-of-car egfr
inhibitor osimertinib tagrisso astrazeneca includ target either resist mutat acquir
follow osimertinib mutat acquir follow osimertinib specif introduc
intend latter set follow osimertinib overal encourag approach
undertak egfr nsclc attract commerci opportun still remain acquir resist popul
look forward addit updat includ timelin ind submiss futur second discuss
cancer immunokinas strategi focu collabor roch headlin introduct
kinas advanc target candid nomin anticip final ep
announc well note bpmc cash equival posit provid suffici runway
reiter outperform rate wlh outperform sign agreement acquir
wlh cash share share wlh class class share base yesterday
close price transact would worth share transact expect close late
earli wlh issu earn releas deal announc morn
updat guidanc wlh press releas confer call also postpon
review sign progress underli weak result
report result sharpli miss expect reduc guidanc reflect miss said isol
network secur incid primarili respons missll comp exclud incid vs consensu
expect comp inflect posit septemb octob compani expect posit comp
market merchandis initi gain traction near-term margin outlook appear slightli less solid tariff-
relat pressur eas end compani appear take aggress approach cost
control new cfo nanci walsh note signific litig risk behind compani liquid
appear suffici encourag chang earli determin whether result sustain
traffic-driven comp growth acceler earn growth show-m stori reduc estim maintain
estim continu rate neutral
review strong quarter momentum like persist
report result beat expect top- bottom-lin basi deliv best quarterli
perform ever includ adjust ebitda guid revenu high end prior rang guid
ebitda exceed prior rang continu distanc pack newer mattress industri player
prove consum will pay premium innov product effect effici
manufactur market distribut product drove strong y/i revenu growth primarili ad
wholesal door mattress firm also wholesal replenish sale import inflect direct-to-
consum dtc growth despit channel mix headwind robust promot labor day weekend gross
margin increas remark bp y/i due partli product mix benefit consum frequent buy premium
product retail store manufactur effici time sg leverag bp y/i due fix cost
leverag strong top line growth effici dtc market plan market cost
may shift view impli sg guidanc conserv particularli given view top-lin momentum
persist inde addit wholesal door growth well replenish sale support continu solid
wholesal growth near-term increas advertis promot new product company-own store
drive continu momentum dtc growth make compani impli guidanc slow revenu growth
appear conserv limit free float share make challeng mani institut investor consid
see potenti increas liquid founder sell signific portion share compani
recent file regist approxim half founder share see higher probabl next
six month see forthcom liquid potenti posit catalyst rais estim reiter outperform
rate
strong result acceler octob earli season pass sale
wedbush view follow brutal weather condit first five month year fun fundament
truli flourish sinc mid-jun recent fall momentum acceler top help make
case much weak last two year larg weather relat distribut growth
moder would expect valuat improv investor gain confid current pay-out sustain
rais price target base modest yield current distribut yield
cedar fair report adjust ebitda versu consensu estim last year
same-park/same-week basi exclud schlitterbahn water park acquir juli adjust
fewer oper day sale impress base increas attend less
declin per-capita spend increas out-of-park revenu
review top line strength persist headwind rise
report result beat unit sale expect gross profit per unit gpu expect miss ebitda
margin ebitda expect cost pressur acceler compani modestli boost unit gpu
forecast reduc outlook ebitda margin impli ebitda suspect would abl
demonstr posit increment margin unit sale beat continu spend drive sale growth
certain extent support gpu ebitda margin remain neg higher sale growth translat higher loss
cash burn unit econom appear attract compani matur market yet case
vast major busi exampl sg per vehicl twice level gpu market enter
sg remain stick point us invest area car buy consum result sharp jump
number car bought consum sharp jump mix retail vehicl sourc channel
benefit retail wholesal gross profit yet driven posit return math base increment
advertis sg purpos increment wholesal profit
increment retail profit quarter base data point compani expect get effici
disciplin buy car consum futur one area remain headwind near-term
look favor unit gpu outlookparticularli financ gpubut invest quasi-vari sg growth
inhibit compani turn profit keep us sidelin even lift target price
reflect higher potenti stronger sale growth
maintain neutral rate sq stock post stronger anticip result believ upcom downward
reset street expect upcom invest combin hefti multipl like cap stock
perform specif highlight includ preliminari guid point yoy revenu growth moder
ex-caviar low flat yoy ebitda margin street expect expans upcom invest phase
sale market seller app priorit high roi area q-q acceler gpv growth driven
larger volum mix gener larger merchant bottom line manag margin dilut near term invest
plan in-lin commentari made septemb nyc advisor event sq under-invest critic sale
maintain outperform rate post anoth beat-and-rais quarter results/futur guid like continu
benefit pro-forma compani new platform servic merchant potenti revenue/cost
synergi believ stock could continu work scenario acceler organ growth combin margin
solid underscor strong market posit execut secular driver
print solid beat rais last night acv y/i constant currenc two point ahead
estim compani call strength high-tech/ semiconductor driven connect autom
automot industri compani close multi-year deal larg semiconductor compani defens
spend continu support growth aerospac vertic overal revenu growth led america
y/i continu trend seen also emea grew y/i driven germani franc off-set weak
didnt repurchas share focus resourc acquisit lstc close nov
automot focu dynardo plan multidisciplinari analysi
remain bullish base strong execut capabl capabl leadership team secular growth
driver electrif autonom technolog trend sustain leadership posit engin
simul reason entri point given outlook acceler double-digit growth
hold earn confer call today et access code ansi confer
well-posit expand svod valuat stretch
clearli tremend opportun revenu growth cord cut rise ott servic like contribut
modest growth player busi expand licens partnership advertis revenu
channel advertis video demand avod partner expect compani reach profit within
next five year spend may remain elev sever year compet tv licens contract
fund intern expans substanti growth opportun think multipl alreadi stretch
therefor maintain neutral rate target
result less impress elev share price requir
revenu million vs estim million consensu million guidanc million
adjust ebitda flat line estim vs consensu million guidanc million non-
loss per share vs estim consensu manag rais guidanc
revenu million million guidanc adjust ebitda lower
million million dataxu acquisit account million lower ebitda addit million
high-end relat expens shift smooth impact shift expens roku
beat margin less impress
fitbit collabor googl began april allow compani collect compet
health solut googl appear intent expand med-tech go head-to-head buy fitbit make
sens tri build yet anoth competitor fitbit fitbit struggl expand health solut googl
provid resourc expand compet highest level maintain neutral rate price target
base equiti valu billion
result line expect
revenu million vs estim million consensu million guidanc million
adjust ebitda million vs estim million consensu million guidanc
million non-gaap ep vs estim consensu guidanc devic
sold flat year-over-year million estim million guidanc year-over-year growth driven
smartwatch sale off-set higher quarter vs guidanc year-over-year decreas
ahead call auction weak drive miss
wednesday even report adjust ebitda estim
short street versu last year non-gaap ep street
estim
versu consensu miss top line margin front all-around poor quarter street
expect continu previou trend wors sale better margin well weaker hotel growth
stronger non-hotel growth continu howev actual result came wors expect nearli everi aspect
host earn call thursday morn et meantim estim price target
adr pressur googl encroach drive miss/fi guid
wedbush view all-in follow exceed expect condit rapidli deterior sinc
follow call late juli disappoint perform lower expect function
company-specif initi ultim get clean medium term increasingli difficult
ignor either macro factor contribut slow adr growth secular threat repres googl
constantli evolv money grab therefor lower price target base price-to-earnings multipl
unchang lower estim equival multipl ebitda/shar estim
report adjust ebitda vs estim street flat y/i
gener downsid rel consensu princip compos weaker profit
ota ebitda vs consensu softer-than-expect profit trivago ebitda vs consensu
vrbo vs street egencia ebitda vs consensu modestli wors
unallocated/interseg overhead cost vs contribut shortfal vs street
strength around gross margin final come
report strong result revenu gross margin expect revenu guidanc well
expect ni guidanc essenti in-lin see strength model uniqu market posit
come concern around macro weak somewhat fade think address investor concern
around growth profit guidanc impli estat servic revenu growth admittedli
easi comp strong nonetheless estat servic beat expect y/i driven improv
agent product expect see continu improv improv agent product
sequenti strong traffic growth expect continu least next six month market
share gain contribut core busi strength start see flywheel come togeth better
mortgag titl revenu nearli doubl y/i market launch earlier grown list
share point faster compar market without transact close use direct
launch two market quarter also expect advertis improv lead better
roi flat spend see long-term structur tailwind continu innov includ high-
margin product like redfin direct opendoor partnership also see better synergi stronger path forward
integr brokerag busi model make key differ expect continu
outperform given steadi macro condit taken togeth give us increas confid outperform rate
result well ahead guidanc expect
book million compar estim million consensu estim million guidanc
million book upsid driven primarili strength among glu three growth game design covet
fashion sport basebal grew double-digit y-o-i collect repres overal book
result part reflect improv user acquisit backdrop casual titl help contribut lower cpi
higher qualiti user design covet fashion adjust ebitda million compar estim
million consensu estim million guidanc million better-than-expect profit
result primarili flow-through top-lin upsid
manag fulli pass upsid guidanc high-level guidanc appear fallen
short investor expect
compani provid high-level guidanc includ book growth importantli exclud new titl
low single-digit rang approxim million headcount expens associ develop new titl
includ guidanc howev adjust ebitda margin includ new titl exit year expect
higher previous forecast book growth includ new titl roughli vs prior
impli consensu rate roughli maintain outperform rate lower price target
compani cover respect research analyst analyst certifi view express research report
accur reflect research analyst person view subject secur compani part
compens directli indirectli relat specif recommend view contain research report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
novemb
novemb
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
